All Stories

  1. Are early post‐discharge physician contacts associated with 30‐day psychiatric re‐hospitalisation? A nationwide claims data based retrospective cohort study in Austria free of immortal time bias
  2. Comparing maximum diameter and volume when assessing the growth of small abdominal aortic aneurysms using longitudinal CTA data: cohort study
  3. Vaccine Development during a Pandemic: General Lessons for Clinical Trial Design
  4. On the use of non-concurrent controls in platform trials: a scoping review
  5. Nationwide analysis of hospital admissions and outcomes of patients with SARS-CoV-2 infection in Austria in 2020 and 2021
  6. Online error rate control for platform trials
  7. Red blood cell transfusion-related eicosanoid profiles in intensive care patients—A prospective, observational feasibility study
  8. Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials
  9. Implementing clinical trial data sharing requires training a new generation of biomedical researchers
  10. Association of immediate versus delayed extubation of patients admitted to intensive care units postoperatively and outcomes: A retrospective study
  11. Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)
  12. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
  13. Online control of the False Discovery Rate in group-sequential platform trials
  14. Impact of adaptive filtering on power and false discovery rate in RNA-seq experiments
  15. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment
  16. STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACC...
  17. Commentary: Two approaches to analyze platform trials incorporating non-concurrent controls with a common assumption
  18. On model-based time trend adjustments in platform trials with non-concurrent controls
  19. Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials”
  20. Rationale for the update algorithm of the graphical approach to sequentially rejective multiple test procedures
  21. Incidence and Outcomes of Cardiopulmonary Resuscitation in ICUs: Retrospective Cohort Analysis
  22. Validation of bedside ultrasound to predict lumbar muscle area in the computed tomography in 200 non-critically ill patients: The USVALID prospective study
  23. Estimands and Complex Innovative Designs
  24. Statistical advising: Professional development opportunities for the biostatistician
  25. Sex Differences in Kidney Transplantation: Austria and the United States, 1978–2018
  26. Platform trials and the future of evaluating therapeutic behavioural interventions
  27. Assessment of tumour-agnostic therapies in basket trials
  28. Robust group sequential designs for trials with survival endpoints and delayed response
  29. Growth prediction model for abdominal aortic aneurysms
  30. Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study
  31. An international comparison of age and sex dependency of COVID-19 deaths in 2020: a descriptive analysis
  32. Analysis of the specificity of a COVID-19 antigen test in the Slovak mass testing program
  33. Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
  34. How reliably can ultrasound help determine muscle and adipose tissue thickness in clinical settings? An assessment of intra- and inter-examiner reliability in the USVALID study
  35. Association of Acute Kidney Injury Receiving Kidney Replacement Therapy With Prognosis of Critically Ill Patients With and Without Cancer: A Retrospective Study
  36. The impact of the SARS‐CoV‐2 pandemic on the ongoing prospective, international, multicentre observational study assessing the preoperative anaemia prevalence in surgical patients (ALICE‐trial)
  37. Evaluation and calibration of SAPS 3 in patients with COVID-19 admitted to intensive care units
  38. Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
  39. The use of external controls: To what extent can it currently be recommended?
  40. Optimizing subgroup selection in two‐stage adaptive enrichment and umbrella designs
  41. Collaborative Platform Trials to Fight COVID‐19: Methodological and Regulatory Considerations for a Better Societal Outcome
  42. An international comparison of age and sex dependency of COVID-19 Deaths in 2020 - a descriptive analysis
  43. Analysis of the specificity of the SD Biosensor Standard Q Ag-Test based on Slovak mass testing data
  44. Are p-values Useful to Judge the Evidence Against the Null Hypotheses in Complex Clinical Trials? A Comment on ”The Role of p-values in Judging the Strength of Evidence and Realistic Replication Expectations”
  45. Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic
  46. Efficient two-stage sequential arrays of proof of concept studies for pharmaceutical portfolios
  47. Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
  48. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19
  49. Analysis of Austrian COVID-19 deaths by age and sex
  50. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review
  51. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials
  52. Optimized multiple testing procedures for nested sub-populations based on a continuous biomarker
  53. A critical review of graphics for subgroup analyses in clinical trials
  54. A multiple comparison procedure for dose‐finding trials with subpopulations
  55. Simultaneous inference for multiple marginal generalized estimating equation models
  56. Time of Day and its Association with Risk of Death and Chance of Discharge in Critically Ill Patients: A Retrospective Study
  57. Quantitative approaches underpinning decision making
  58. Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873
  59. Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations
  60. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
  61. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
  62. Applicability and added value of novel methods to improve drug development in rare diseases
  63. Recent advances in methodology for clinical trials in small populations: the InSPiRe project
  64. Subgroup identification in clinical trials via the predicted individual treatment effect
  65. Design and estimation in clinical trials with subpopulation selection
  66. A proposal for a new PhD level curriculum on quantitative methods for drug development
  67. Methods for the analysis of multiple endpoints in small populations: A review
  68. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup
  69. Statistical analysis of Goal Attainment Scaling endpoints in randomised trials
  70. Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker
  71. Optimal exact tests for multiple binary endpoints
  72. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function
  73. Marketing authorisation of orphan medicines in Europe from 2000 to 2013
  74. Approaches to sample size calculation for clinical trials in rare diseases
  75. Optimized adaptive enrichment designs
  76. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
  77. Weekends affect mortality risk and chance of discharge in critically ill patients: a retrospective study in the Austrian registry for intensive care
  78. Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)
  79. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov
  80. “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?
  81. Estimation after blinded sample size reassessment
  82. Optimizing Trial Designs for Targeted Therapies
  83. Multi-arm group sequential designs with a simultaneous stopping rule
  84. Directions for new developments on statistical design and analysis of small population group trials
  85. Determination of the optimal sample size for a clinical trial accounting for the population size
  86. Preface
  87. Fallback tests for co-primary endpoints
  88. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions
  89. Adaptive Designs for Clinical Trials with a Time to Event Endpoint
  90. Evidence, eminence and extrapolation
  91. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels
  92. Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery
  93. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review
  94. Decision-theoretic designs for small trials and pilot studies: A review
  95. Sample size reassessment for a two-stage design controlling the false discovery rate
  96. MCP2013 - 8th International Conference on Multiple Comparison Procedures
  97. Adaptive designs for subpopulation analysis optimizing utility functions
  98. Adaptive graph-based multiple testing procedures
  99. Flexible Designs
  100. Flexible Designs
  101. Bridging the gap: a review of dose investigations in paediatric investigation plans
  102. Connections between permutation andt-tests: relevance to adaptive methods
  103. Sharing clinical trial data on patient level: Opportunities and challenges
  104. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients
  105. Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union
  106. Morphine Decreases Clopidogrel Concentrations and Effects
  107. Effect of intensive care after cardiac arrest on patient outcome: a database analysis
  108. Detection of epistatic effects with logic regression and a classical linear regression model
  109. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
  110. Adaptive Budgets in Clinical Trials
  111. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs
  112. Flexible Designs
  113. MCP2011-The 7th international conference on multiple comparison procedures
  114. Modeling and Simulation to Optimize the Design and Analysis of Confirmatory Trials, Characterize Risk-Benefit, and Support Label Claims
  115. Wideband UHF ISM-band transceiver supporting multichannel reception and DSSS modulation
  116. Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude
  117. Author's reply
  118. Bridging the gap: a review of dose-investigation studies in paediatric investigation plans
  119. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients
  120. Unplanned adaptations before breaking the blind
  121. Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine
  122. False discovery rate control in two-stage designs
  123. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
  124. Impact of dental implant length on early failure rates: a meta-analysis of observational studies
  125. Special Issue for Dealing with Multiplicity in Drug Development: Current State and New Directions – Guest Editors' Note
  126. Familywise Error Control in Multi-Armed Response-Adaptive Two-Stage Designs
  127. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
  128. Cross-platform comparison of microarray data using order restricted inference
  129. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study
  130. MCP2009 - 6th International Conference on Multiple Comparison Procedures
  131. Availability of Mental Health Service Providers and Suicide Rates in Austria: A Nationwide Study
  132. Availability of Mental Health Service Providers and Suicide Rates in Austria: A Nationwide Study
  133. Early postpartum hysterectomy: incidence and risk factors
  134. Skateboarding Injuries in Vienna: Location, Frequency, and Severity
  135. On the ropivacaine-reducing effect of low-dose sufentanil in intrathecal labor analgesia
  136. Post hoc power estimation in large-scale multiple testing problems
  137. Adaptive Designs and Confirmatory Hypothesis Testing
  138. Hunting for Significance With the False Discovery Rate
  139. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
  140. Adaptive designs for confirmatory clinical trials
  141. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease
  142. Optimal choice of the number of treatments to be included in a clinical trial
  143. A graphical approach to sequentially rejective multiple test procedures
  144. Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double-blind study
  145. Selection and bias-Two hostile brothers
  146. Diagnostic accuracy and reliability of muscle strength and endurance measurements in patients with chronic low back pain
  147. Correction
  148. Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial
  149. MCP2007 - 5th International Conference on Multiple Comparison Procedures
  150. Optimized multi-stage designs controlling the false discovery or the family-wise error rate
  151. Exact Confidence Bounds Following Adaptive Group Sequential Tests
  152. A powerful multiple testing procedure improving the Bonferroni test
  153. A Note on repeated p-values for group sequential designs
  154. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy
  155. Adaptive Dunnett tests for treatment selection
  156. Flexible Designs
  157. Vergleichende Analyse der Messwertergebnisse von zwei Dynamometern zur Messung der isokinetischen Kraft der kniegelenksbewegenden Muskulatur
  158. The scientific work of Peter Bauer
  159. Physiotherapy-Based Rehabilitation Following Disc Herniation Operation
  160. Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans
  161. Elevated levels of interleukin-1?-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction
  162. Repeated confidence intervals for adaptive group sequential trials
  163. Flexible Designs
  164. Clinical Features, Classification and Prognosis of Migraine and Tension-Type Headache in Children and Adolescents: A Long-Term Follow-Up Study
  165. Diuretic potential of energy drinks
  166. On the efficiency of adaptive designs for flexible interim decisions in clinical trials
  167. Implant survival in mandibles of irradiated oral cancer patients
  168. Flexible Designs
  169. Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group
  170. Attainability of boundary points under reinforcement learning
  171. Two-stage designs for experiments with a large number of hypotheses
  172. Übersetzung und psychometrische Austestung des Western-Ontario-Rotator-Cuff-Index (WORC) für den Gebrauch in deutscher Sprache
  173. Correlations between Self-Rated Fatigue with Quality of Life, and Social Participation in Viennese Outpatients Suffering from Advanced Cancer During Palliative Chemotherapy
  174. Übersetzung und psychometrische Austestung des Rotator Cuff Quality-of-Life Measure (RC-QOL) für den Gebrauch im deutschen Sprachraum
  175. Testing and estimation in flexible group sequential designs with adaptive treatment selection
  176. Long-term implant survival in the grafted maxilla: results of a 12-year retrospective study
  177. The German version of the Oxford shoulder score?cross-cultural adaptation and validation
  178. Conditional Rejection Probabilities of Student'st-test and Design Adaptations
  179. HSP-72 Expression in Pre-Transplant Donor Kidney Biopsies and Post-Transplant Outcome
  180. Rehabilitation of the severely atrophied maxilla by horseshoe Le Fort I osteotomy (HLFO)
  181. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.-H. Müller,Statistics in Medicine 2001;20: 3741–3751
  182. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy
  183. Muscle Fatigue and Fatigue-Related Biomechanical Changes During a Cyclic Lifting Task
  184. Sequential Tests for Noninferiority and Superiority
  185. Factors That Influence the Duration of Splint Wear in Peripheral Nerve Lesions
  186. Impact of Pneumococcal Vaccination on Morbidity and Mortality of Geriatric Patients: A Case-Controlled Study
  187. Issues in designing flexible trials
  188. Statistical Methods for Clinical Trials. M. X. Norleans, Marcel Dekker, New York, 2001. No. of pages: 257. ISBN 0-8247-0467-3
  189. Recursive Combination Tests
  190. Short segment stimulation of the anterior transposed ulnar nerve at the elbow
  191. Multiple Testing for Identifying Effective and Safe Treatments
  192. CROSS-CULTURAL ADAPTATION OF THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOR GERMAN-SPEAKING PATIENTS
  193. Interim Analysis and Sample Size Reassessment
  194. Load-dependence of fatigue related changes in tremor around 10 Hz
  195. Adaptive Two Stage Designs and the Conditional Error Function
  196. The efficiency of adapting aspiration levels
  197. Win–Stay, Lose–Shift Strategies for Repeated Games—Memory Length, Aspiration Levels and Noise
  198. Cycling in a stochastic learning algorithm for normal form games